[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Bushell et al., 2006 - Google Patents

CD25+ T-REGS GENERATED BY EXPOSURE TO MODEL PROTEIN ANTIGENS PREVENT SKIN AND HEART ALLOGRAFT REJECTION BY 'BYSTANDER …

Bushell et al., 2006

Document ID
17928847698710359621
Author
Bushell A
Karim M
Feng G
Wood K
Publication year
Publication venue
Transplantation

External Links

Snippet

208 Abstract# 209 Abstract# 210 Page 1 CONCURRENT SESSION 18: EXPERIMENTAL IMMUNOSUPPRESSION 136 World Transplant Congress 2006 vector or buffer solution alone. In additional experiments, PDL-1 gene transfer combined with a sub-therapeutic dose of …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Yuan et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo
Bresson et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
Ito et al. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway
Ephrem et al. Modulation of T reg cells/T effector function by GITR signaling is context–dependent
Chen et al. Role of double-negative regulatory T cells in long-term cardiac xenograft survival
US9018006B2 (en) Stable Tregs and related materials and methods
Albring et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression
Kinnear et al. A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen
KR20190016507A (en) T-cell receptors that recognize frame-shift mutants of TGF [beta] RII
JP2017503810A (en) Improved cell compositions and methods for cancer treatment
Asavaroengchai et al. An essential role for IFN-γ in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation
D’Addio et al. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival
US9624469B2 (en) Regulatory immune cells with enhanced targeted cell death effect
Krakow et al. Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment
US9822161B2 (en) ILT3 polypeptides and uses thereof
JP2020055845A (en) An isolated peptide derived from donor mhc and uses thereof
Simon et al. Regulatory T cells inhibit Fas ligand‐induced innate and adaptive tumour immunity
Bushell et al. CD25+ T-REGS GENERATED BY EXPOSURE TO MODEL PROTEIN ANTIGENS PREVENT SKIN AND HEART ALLOGRAFT REJECTION BY ‘BYSTANDER REGULATION’: REGULATORY T CELLS WITHOUT ALLOANTIGEN EXPOSURE.
Li et al. Rapid Functional Decline of Activated and Memory Graft-versus-Host–Reactive T Cells Encountering Host Antigens in the Absence of Inflammation
Unger et al. Chronic CD40L blockade is required for long-term cardiac allograft survival with a clinically relevant CTLA4-Ig dosing regimen
EP3958887B1 (en) Medical uses for inducing or restoring immune tolerance
Vlad et al. RECOMBINANT SOLUBLE ILT3 PROTEIN INDUCES THE DIFFERENTIATION OF ALLOSPECIFIC T SUPPRESSOR CELLS.
Zang et al. TREATMENT WITH AN MHC CLASS II DERIVED PEPTIDE INHIBITS ALLOANTIBODY PRODUCTION AND DECREASED T CELL CLONAL EXPANSION IN VIVO.
US20230277597A1 (en) Haploidentical mixed chimerism for treating autoimmune diseases
Lee et al. Tolerance Induction Through Megadose Bone Marrow Transplantation with Two-Signal Blockade1